Previous 10 | Next 10 |
Protagonist Therapeutics Appoints Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology Renowned Expert in Gastrointestinal Diseases Joins Company to Lead the Advancement and Expansion of Its Pipeline PR Newswire NEWARK, Calif. , Se...
An ETF that chooses solely by IBM's Watson artificial intelligence is still keeping its cash balance to a minimum with the major averages at or near record highs. The AI Powered Equity ETF (NYSEARCA:AIEQ) is trailing the S&P 500 (SP500) (NYSEARCA:SPY) slightly year to date, up 17.5%, comp...
Protagonist Therapeutics Announces Resolution of Contract Dispute with Zealand Pharma PR Newswire NEWARK, Calif. , Aug. 10, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced it has resolved it...
Protagonist Therapeutics Reports Second Quarter 2021 Financial Results and Recent Company Progress PR Newswire NEWARK, Calif. , Aug. 4, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) ("Protagonist" or "the Company") today reported its financia...
Protagonist Therapeutics Announces Amendment of Agreement with Janssen Biotech for the Continued Development and Commercialization of IL-23 Antagonists Amended Agreement Provides for Janssen to Lead Worldwide Development and Commercialization of Multiple Compounds in Parallel an...
Biotech stocks had a muted first half with the S&P Biotech Index down year-to-date, and more than 20% lower from its mid-February peak. The decline in biotech stocks coincided with a spike in interest rates and stabilizing interest rates can provide a boost to valuations. M&am...
janiecbros/E+ via Getty Images Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotech’s (XBI) have fallen about 25% from their February highs, according to Jefferies. Biotech deals may pick up after a 3-6 month of a large "drawdown" and as prices "normalize" f...
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
Protagonist Therapeutics (PTGX) announces the closing of its previously announced underwritten public offering of 3.5M shares for gross proceeds of $132.2M.The offering included 456K shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a...
Protagonist Therapeutics, Inc. Announces Closing of $132.2 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire NEWARK, Calif. , June 18, 2021 /PRNewswire/ -- Protagonist Therapeutics, In...
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE /...